Skip to content
Ibex™ Lonza facilit in Visp Switzerland

Lonza acquires Dutch biotech company Synaffix

Share this article

The Valais-based pharmaceutical subcontractor will pay an initial €100 million, with subsequent milestone payments of up to a further €60 million.



The deal will strengthen Lonza’s portfolio of antibody-drug conjugates (ADCs) through the integration of Synaffix’s platform. According to a recent estimate relayed by Lonza, the ADC market is set to pass the $22 billion mark by 2030.


Ulrich Osswald, Vice President, Licensing, Lonza, commented: “The Synaffix ADC technology is the gold standard, helping clinical-stage developers to design potentially curative therapies in areas of high unmet medical need. The acquisition of Synaffix underlines the strategic position of bioconjugates within Lonza’s portfolio, expands our offering in this fast-growing market and enhances our value proposition for clinical customers. With Synaffix, our combined industry-leading knowledge and capabilities have the capacity to support both clinical and commercial needs.”


Peter van de Sande, CEO, Synaffix, added: “On our mission to bring Synaffix’s ADC technologies to patients, we are excited to become part of Lonza and thus, through strong and immediate synergies, ensure a robust technology and manufacturing platform for our licensees as they progress into the late stage clinical and commercial development phase. We can now also leverage the potential offered by Lonza to fast-track technology innovations in bioconjugates beyond cytotoxic ADCs. We look forward to working closely with our colleagues at Lonza for the continued enablement of promising potential medicines for patients in need.”


As a Lonza company, Synaffix will continue to operate under the Synaffix name and further expand its operations in Oss (NL) to cater for further innovation and growth.


The acquisition reflects Lonza’s strategy to differentiate through technology and innovation. From its leading bioconjugation offering, to the commercial manufacture of cell and gene therapies and support in producing live biotherapeutics, Lonza’s manufacturing technologies help customers deliver innovative new therapies to patients.


Synaffix will continue to operate under its current name and to develop its activities at its Oss site.



Source: press release